FUJIFILM Cellular Dynamics introduced new human iPSC-derived iCell® blood-brain barrier isogenic kit. This kit is specifically tailored for researchers and scientists working in the field of neuroactive drug exploration.
The first-of-its-kind kit appears to provide a comprehensive solution for researchers, offering a combination of human iPSC-derived cells that mimic the different components of the blood-brain barrier, including endothelial cells, pericytes, and astrocytes.
The development of this iCell Blood-Brain Barrier Isogenic Kit is a promising step forward in the field of neuroscience and drug discovery. It has the potential to accelerate the development of novel treatments and enhance the knowledge of CNS disorders, ultimately benefiting patients, caregivers, and the scientific community.
Furthermore, having a reliable model like this can also help researchers gain deeper insights into the underlying biology of CNS disorders. It can provide a platform to study disease mechanisms, identify potential therapeutic targets, and refine treatment approaches.
As a result, this kit has the potential to contribute significantly to understand CNS physiology and improve treatment options for patients with neurological disorders.
This kit's ability to simulate the barrier's properties and mimic its physiological behaviour is essential for accurately assessing how drugs and other molecules interact with the blood-brain barrier. This, in turn, can aid in drug discovery, development, and toxicological studies specifically targeting CNS disorders.
By using this model, researchers can better understand the passage of substances through the blood-brain barrier, potentially leading to more effective treatments for various neurological conditions.
